Needham Sticks to Its Buy Rating for Cara Therapeutics (CARA)

By Austin Angelo

In a report released today, Alan Carr from Needham maintained a Buy rating on Cara Therapeutics (CARAResearch Report), with a price target of $35.00. The company’s shares closed last Monday at $18.59.

According to TipRanks.com, Carr is a 1-star analyst with an average return of -0.1% and a 43.4% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Lexicon Pharmaceuticals, and Phathom Pharmaceuticals.

Currently, the analyst consensus on Cara Therapeutics is a Strong Buy with an average price target of $32.67.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.55 and a one-year low of $12.19. Currently, Cara Therapeutics has an average volume of 552.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CARA Therapeutics, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain.